One of the most relevant TKRi in veterinary clinics is toceranib phosphate (Palladia), which is a multi-target TKRi that acts against vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptors (PDGFR), c-Kit, colony-stimulating factor 1 receptor (CSF1R) and fms-like tyrosine kinase (FLT3), which are commonly altered in many cancers, including OSA [88]. This evidence concerns the gene KIT and obstructive sleep apnea syndrome.